Literature DB >> 20303383

Design of Ad5F35 vectors for coordinated dual gene expression in candidate human hematopoietic stem cells.

Manli Na1, Xiaolong Fan.   

Abstract

OBJECTIVE: Adenoviral vector-mediated gene expression is an attractive approach to manipulate or report gene expression in human hematopoietic stem cells (HSC) when transient gene expression is preferred. Previous studies have demonstrated that fiber-retargeted Ad5F35 vectors can mediate efficient gene transfer into human HSCs. In this study, we investigated the potential of bi-directional promoter-controlled Ad5F35 vector for coordinated dual gene expression in candidate HSCs.
MATERIALS AND METHODS: We have engineered Ad5F35-DeltaLNGFR-BiDp encoding kinase domain deleted low-affinity NGF receptor (DeltaLNGFR) and green fluorescent protein (GFP) expression cassette controlled by a synthetic bi-directional promoter, which is composed of human phosphoglycerate kinase promoter and minimal core promoter from human cytomegalovirus. The expression pattern of DeltaLNGFR and GFP following Ad5F35-DeltaLNGFR-BiDp gene transfer in various cell types, including candidate HSCs, was compared to Ad5F35-DeltaLNGFR-IRES vector encoding phosphoglycerate kinase promoter-controlled bicistronic expression cassette for DeltaLNGFR and GFP.
RESULTS: Using Ad5F35-DeltaLNGFR-BiDp, we demonstrated a coordinated, high-level dual gene expression in leukemic cells and cord blood CD34(+) cells. However, the ability of Ad5F35-DeltaLNGFR-BiDp-GFP for coordinated dual gene expression varied significantly between repopulating progenitor cells. In nonobese diabetic severe combined immune deficient mice bone marrow transplantation assay, sorted CD34(+)/DeltaLNGFR(+)/GFP(+) cells following infection with Ad5F35-DeltaLNGFR-BiDp showed predominantly myeloid lineage reconstitution with limited lymphoid lineage differentiation capacity, whereas the CD34(+)/DeltaLNGFR(+)/GFP(-) cells exhibited both myeloid and lymphoid reconstitution.
CONCLUSIONS: This study indicates that bi-directional promoter-controlled Ad5F35 vector, such as Ad5F35-DeltaLNGFR-BiDp, can be particularly useful for manipulation of myeloid progenitor cells and potentially in myeloid lineage leukemic cells as well. Copyright 2010 ISEH - Society for Hematology and Stem Cells. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20303383     DOI: 10.1016/j.exphem.2010.03.007

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  4 in total

1.  Adenoviral Type 35 and 26 Vectors with a Bidirectional Expression Cassette in the E1 Region Show an Improved Genetic Stability Profile and Potent Transgene-Specific Immune Response.

Authors:  Marija Vujadinovic; Kerstin Wunderlich; Benoit Callendret; Marina Koning; Mark Vermeulen; Barbara Sanders; Esmeralda van der Helm; Adile Gecgel; Dirk Spek; Karin de Boer; Masha Stalknecht; Jan Serroyen; Maria Grazia Pau; Hanneke Schuitemaker; Roland Zahn; Jerome Custers; Jort Vellinga
Journal:  Hum Gene Ther       Date:  2017-11-30       Impact factor: 5.695

2.  Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis.

Authors:  Baocan Wang; Wenxi Li; Yingwei Chen; Yuqin Wang; Chao Sun; Yuanwen Chen; Hanming Lu; Jiangao Fan; Dingguo Li
Journal:  Med Sci Monit       Date:  2012-10

3.  A versatile transposon-based technology to generate loss- and gain-of-function phenotypes in the mouse liver.

Authors:  Anna Georgina Kopasz; Dávid Zsolt Pusztai; Réka Karkas; Liza Hudoba; Khaldoon Sadiq Ahmed Abdullah; Gergely Imre; Gabriella Pankotai-Bodó; Ede Migh; Andrea Nagy; András Kriston; Péter Germán; Andrea Bakné Drubi; Anna Molnár; Ildikó Fekete; Virág Éva Dani; Imre Ocsovszki; László Géza Puskás; Péter Horváth; Farkas Sükösd; Lajos Mátés
Journal:  BMC Biol       Date:  2022-04-01       Impact factor: 7.431

4.  [Mechanisms of recombinant adenovirus-mediated SD-HA fusion protein proliferation inhibition and induced apoptosis of K562 cells].

Authors:  Y Huang; P Zhang; L Du; M Gui; W L Feng; Z Peng
Journal:  Zhonghua Xue Ye Xue Za Zhi       Date:  2018-04-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.